Pathology reporting of pancreatic cancer following neoadjuvant therapy: Challenges and uncertainties. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Verbeke, C.; Löhr, M.; Severin Karlsson, J.; Del Chiaro, M.
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 1(2015)
• Page Start: 17
• Page End: 26
• Publication Date: 2015-01
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2014.11.002
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab015"> <title id="st125">Highlights</title> <sec> <p id="sp0065"> <list id="l0085"> <list-item id="o0365"> <label></label> <p id="p0610">Key outcome measures for neoadjuvant treatment (NAT) of pancreatic cancer (PC) are pathology-based.</p> </list-item> <list-item id="o0370"> <label></label> <p id="p0615">Pathology examination of PC following NAT is difficult and lacks consensus.</p> </list-item> <list-item id="o0375"> <label></label> <p id="p0620">Variation in sampling and regression grading affects the assessment of tumour response.</p> </list-item> <list-item id="o0380"> <label></label> <p id="p0625">Margin assessment following NAT lacks an evidence-based definition.</p> </list-item> <list-item id="o0385"> <label></label> <p id="p0630">Lack of uniformity in pathology assessment hampers the study of the efficacy of NAT of PC.</p> </list-item> </list> </p> </sec> </abstract>